Test Price
2,800 AED✅ Home Collection Available
SCN5A Gene (Ventricular Fibrillation, Familial Paroxysmal Type 1) Genetic Test in UAE | AED 2,800 | DHA Licensed
Executive Summary & Core Metrics
Clinical Grade Molecular Diagnostics for Life-Threatening Arrhythmia Risk Assessment
- Analytical Accuracy: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Next-Generation Sequencing Platform.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM – 11 PM.
- Clinical Guidance: Telephonic Post-Test Genetic Counseling by DHA-licensed Consultant Medical Geneticist.
- Insurance & Billing: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The SCN5A gene test employs high-coverage Next-Generation Sequencing (NGS) to detect pathogenic and likely pathogenic variants associated with familial paroxysmal ventricular fibrillation type 1. Early identification of deleterious mutations in the cardiac sodium channel gene enables cardiologists and geneticists to stratify sudden cardiac death risk and guide decisions regarding implantable cardioverter-defibrillator (ICD) placement, lifestyle modification, and family cascade screening.
| Feature | SCN5A NGS Panel | Conventional Sanger Sequencing |
|---|---|---|
| Sequencing Depth | 100x coverage across all exons and splice sites | Single-pass capillary reads, limited sensitivity for mosaicism |
| Variant Detection | SNVs, indels, and CNVs with ACMG/AMP classification | SNVs only; no structural variant resolution |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Genetic Counseling | Included pre- and post-test tele-counseling | Not included |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403) states: “Genetic testing for SCN5A-related channelopathies provides critical information for sudden cardiac death prevention, yet results must always be interpreted within the context of a complete three-generation pedigree and clinical phenotype. A negative result does not exclude all inherited arrhythmia syndromes, and a variant of uncertain significance requires cautious familial segregation analysis before any therapeutic action is taken.”
Advisory: Medication Continuation
⚠ Medication Warning
Do not discontinue, alter, or adjust any prescribed antiarrhythmic therapy, beta-blocker, or other cardiac medication based solely on genetic test results. Always consult your treating cardiologist before making changes to your medication regimen. This genetic test does not replace urgent clinical evaluation for acute cardiac symptoms.
Exclusion Criteria & Emergency Red Flags
Safety Exclusion & Emergency Red Flags
- Exclusion Criteria: Specimens received without valid informed consent; prenatal samples without prior genetic counseling; individuals unable to provide a documented three-generation family pedigree; requests without a clear clinical indication for cardiac channelopathy evaluation.
- Emergency Red Flags: If you experience syncope (fainting), seizure-like activity, unexplained palpitations accompanied by chest pain or shortness of breath, seek immediate emergency medical care. This test is intended for elective risk stratification, not acute diagnosis.
Patient FAQ & Clinical Guidance
1. What is the SCN5A gene test for familial ventricular fibrillation?
This molecular genetic test analyzes the entire coding region and splice junctions of the SCN5A gene using next-generation sequencing. It identifies inherited mutations that increase risk for familial paroxysmal ventricular fibrillation type 1, Brugada syndrome, long QT syndrome type 3, and sudden cardiac death. Results help your cardiologist and geneticist determine appropriate surveillance, preventive therapies, and family screening strategies.
2. How should I prepare for the SCN5A genetic test?
No fasting or special preparation is required. A standard venous blood draw (5–10 mL) collected in an EDTA tube or a DNA spot on an FTA card is sufficient. Our mobile phlebotomist can collect the sample at your home between 8 AM and 11 PM. A mandatory pre-test genetic counseling session will be scheduled to document your family history and discuss possible outcomes, including variants of uncertain significance.
3. Can this test be performed on minors in the UAE?
Yes, clinical genetic testing for actionable cardiac channelopathies in minors is permitted under UAE law when there is a clear medical indication and written informed consent from a parent or legal guardian. Testing must be accompanied by pre- and post-test genetic counseling to ensure the child’s future autonomy is respected. Asymptomatic predictive testing in children is governed by strict ethical guidelines and requires multidisciplinary approval.
4. What do my SCN5A genetic test results mean for my family?
Because SCN5A-related cardiac channelopathies follow an autosomal dominant inheritance pattern, first-degree relatives (parents, siblings, children) have a 50% chance of carrying the same familial variant. A positive result enables targeted cascade screening to identify at-risk family members before symptoms develop. A negative result in a known family reduces that individual’s risk to the general population level but does not rule out other genetic causes of arrhythmia.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Health Information Governance: All genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety, informed consent, and patient rights are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory operates under ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and holds DHA Facility License No. 1143. All clinical interpretations are performed by DHA-licensed Consultant Medical Geneticists following current American College of Medical Genetics and Genomics (ACMG) guidelines.
Clinical & Logistical Metadata
| Test Name | SCN5A Gene (Ventricular Fibrillation, Familial Paroxysmal Type 1) Genetic Test |
| Price (AED) | AED 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or DNA (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger Validation |
| ICD-10-CM Code | I49.01 |
| LOINC Code | 21636-6 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | DNA Labs UAE | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians